ISIN | CH1205452688 |
---|---|
Valor Number | 120545268 |
Bloomberg Global ID | |
Fund Name | Bellevue Healthcare Strategy I2 EUR |
Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fund Provider | Bellevue Asset Management AG |
Representative in Switzerland | |
Distributor(s) |
Zürcher Kantonalbank Zürich Phone: +41 44 293 93 93 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Switzerland |
Issuing Condition | Special conditions apply to the issue of units |
Redemption Condition | Special conditions apply to the redemption of units |
Investment Strategy *** | N/A |
Peculiarities |
Current Price * | 1,056.10 EUR | 18.09.2024 |
---|---|---|
Previous Price * | 1,059.97 EUR | 17.09.2024 |
52 Week High * | 1,085.64 EUR | 30.08.2024 |
52 Week Low * | 925.09 EUR | 30.10.2023 |
NAV * | 1,056.10 EUR | 18.09.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 220,867,383 | |
Unit/Share Assets *** | 47,273,799 | |
Trading Information SIX |
YTD Performance | +8.68% |
29.12.2023 - 18.09.2024
29.12.2023 18.09.2024 |
---|---|---|
YTD Performance (in CHF) | +10.08% |
29.12.2023 - 18.09.2024
29.12.2023 18.09.2024 |
1 month | +0.03% |
19.08.2024 - 18.09.2024
19.08.2024 18.09.2024 |
3 months | +2.95% |
18.06.2024 - 18.09.2024
18.06.2024 18.09.2024 |
6 months | +5.60% |
18.03.2024 - 18.09.2024
18.03.2024 18.09.2024 |
1 year | +6.96% |
18.09.2023 - 18.09.2024
18.09.2023 18.09.2024 |
2 years | +5.78% |
06.10.2022 - 18.09.2024
06.10.2022 18.09.2024 |
3 years | - | - |
5 years | - | - |
Equity Participation Rate in % | 96.95 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Vertex Pharmaceuticals Inc | 3.35% | |
---|---|---|
Regeneron Pharmaceuticals Inc | 3.17% | |
UnitedHealth Group Inc | 3.13% | |
Insulet Corp | 3.09% | |
McKesson Corp | 3.09% | |
HCA Healthcare Inc | 3.07% | |
Eli Lilly and Co | 3.04% | |
Boston Scientific Corp | 2.99% | |
IQVIA Holdings Inc | 2.94% | |
UCB SA | 2.91% | |
Last data update | 31.07.2024 |
TER | 0.61% |
---|---|
TER date | 29.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.60% |
Ongoing Charges *** | |
SRRI ***
|
|
SRRI date *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |